Anagram Therapeutics, Inc.
Kathryn Kilroy has a diverse work experience spanning several industries. Kathryn currently holds the position of Director of Business Operations at Anagram Therapeutics, Inc. starting from January 2023. Prior to this role, they served as the Director of Business Operations at Synspira from January 2019 to April 2023. From November 2011 to April 2017, they were the Associate Director of Business Operations at Alcresta Therapeutics. Kathryn also held the position of Associate Director, Business Operations at Allena Pharmaceuticals, Inc., from November 2011 to May 2015. Kathryn has experience in membership services, having worked as the Director of Member Services at MassBio from June 2011 to November 2011 and as the Manager of Member Services from November 2008 to October 2011. Additionally, Kathryn served as the Manager of Global Events at CERA from January 2006 to November 2008. Kathryn'searly career includes a promotion management role at Polaroid from 1991 to 1999, where they focused on building new partnerships to increase distribution channels.
Kathryn Kilroy holds a Bachelor's degree in Business Administration from Saint Michael's College, although no specific information regarding the start and end year of their education is available.
This person is not in any teams
Anagram Therapeutics, Inc.
Anagram is a clinical stage company leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. Malabsorption syndromes and nutrient metabolism disorders prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. ANG003, Anagram’s lead product is intended for the treatment of malabsorption and exocrine pancreatic insufficiency and is a new class of broad-spectrum digestive enzyme replacement therapy.